Identification of APEX2 as an oncogene in liver cancer

Figure 1 APEX1 and APEX2 expression analysis in pan-cancer. A: The pan-cancer with adjacent non-tumor and tumor tissues were subjected to the TIMER tool, and the APEX1 and B: APEX2 expression were compared with tumor tissues of each cancer type. ^aP < 0.05, ^bP < 0.01, ^cP < 0.001 vs tumor tissues of each cancer type. TPM: Transcript per million; BLCA: Bladder urothelial carcinoma; BRCA: Breast invasive carcinoma; CHOL: Cholangiocarcinoma; COAD: Colon adenocarcinoma; ESCA: Esophageal carcinoma; HNSC: Head and neck squamous cell carcinoma; KICH: Kidney chromophobe; KIRC: Kidney renal clear cell carcinoma; KIRP: Kidney renal papillary cell carcinoma; LIHC: Liver hepatocellular carcinoma; LUAD: Lung adenocarcinoma; LUSC: Lung squamous cell carcinoma; PRAD: Prostate adenocarcinoma; READ: Rectum adenocarcinoma; STAD: Stomach adenocarcinoma; THCA: Thyroid carcinoma; UCEC: Uterine corpus endometrial carcinoma.